Progress in reducing the global impact of cancer is slow, but the Galleri blood test, developed by the American company Grail, has sparked hope. It can detect signals from 50 types of cancer, with a correct identification rate of 62% for individuals with positive results and a specificity of 99.6% for those without cancer. However, 38% of positive results are false alarms, and the sensitivity of the test is only 40.4%, meaning that many cases of cancer could be missed. Although the test could become a useful tool in future screening programs, its high cost and the lack of evidence that its widespread use reduces cancer mortality are important considerations. In conclusion, although preliminary data is promising, the Galleri test is not a complete solution.
Sources
Latest News
21:45
The Romanian Lottery announces the winning of the largest prize in the history of Loto 6/49, worth over 52.83 million lei, by a player from Oradea.
21:39
United Kingdom: A passenger train derailed in the Lewes area, East Sussex
21:18
The governor of the BNR stated that Romania does not meet the necessary criteria for adopting the euro.
21:13
West London recorded 38.1 degrees Celsius on Thursday, becoming the hottest day since 2026. The United Kingdom is facing its fifth heatwave.
See more news